NCT04672889

Brief Summary

In order to understand the life history of the breast milk flora, explore its composition, source of strains, and ability to colonize the baby's intestinal environment, to find out strains with the potential of probiotics in breast milk

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 10, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

December 17, 2020

Completed
11 months until next milestone

Study Start

First participant enrolled

November 1, 2021

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2024

Completed
Last Updated

January 10, 2025

Status Verified

January 1, 2025

Enrollment Period

2.9 years

First QC Date

December 10, 2020

Last Update Submit

January 8, 2025

Conditions

Outcome Measures

Primary Outcomes (6)

  • Microflora of mother's feces

    Collect mother's feces for bacterial analysis.The mother's feces use Qiagen stool mini kit to extract DNA, and then use the intestinal bacteria primers to detect the presence of intestinal bacteria in the feces.

    4-6 weeks after the baby is born

  • Group. B Streptococcus (GBS) screening

    Use sterile cotton sticks for vaginal samples, and then perform Group. B Streptococcus (GBS) screening

    35-37 weeks of pregnancy

  • The microflora of maternal blood

    Use venous blood to collect 20 ml of mother's blood for bacterial analysis.The mother's blood uses Qiagen DNA isolation mini kit to extract DNA, and then uses intestinal bacteria primers to detect the presence of intestinal bacteria in the blood

    4-6 weeks after the baby is born

  • Metabolic analysis of maternal urine

    Collect 10 ml of mother's urine for intestinal dysbiosis analysis. Use Qiagen DNA isolation mini kit to extract DNA from the mother's urine, and then use the intestinal bacteria primer to detect the presence of intestinal bacteria in the urine.

    4-6 weeks after the baby is born

  • Bacteria analysis of breast milk

    Collect 10 ml of breast milk for bacterial phase analysis.Use Qiagen DNA isolation mini kit to extract DNA from breast milk, and then use intestinal bacteria primers to detect whether the breast milk contains intestinal bacteria.

    4-6 weeks after the baby is born

  • Bacteria analysis of infant feces

    Collect baby feces for bacterial phase analysis.Use Baby feces use Qiagen stool mini kit to extract DNA, and then use intestinal bacteria primers to detect the presence of intestinal bacteria in the feces.

    4-6 weeks after the baby is born

Study Arms (2)

Placebo

PLACEBO COMPARATOR

consume 1 sachet per day for 1 months

Dietary Supplement: Placebo

Babyguard® Breast Milk Probiotics

EXPERIMENTAL

consume 1 sachet per day for 1 months

Dietary Supplement: Babyguard® Breast Milk Probiotics

Interventions

PlaceboDIETARY_SUPPLEMENT

consume 1 sachet per day for 1 months

Placebo

consume 1 sachet per day for 1 months

Babyguard® Breast Milk Probiotics

Eligibility Criteria

Age20 Years - 65 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsThose who are 20 years old and pregnant
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • At least 20 years old, pregnant women with non-high-risk pregnancy risk assessed by obstetricians and gynecologists, healthy mothers and infants with no abnormal obstetric examination results

You may not qualify if:

  • Pregnant women who have used oral or injectable antibiotics within three months before delivery, or women who need a cesarean section for any reason during pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Taiwan University Hospital

Taipei, Zhongzheng District, 100225, Taiwan

Location

Study Officials

  • Ming Shiang Wu, Doctor

    National Taiwan University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 10, 2020

First Posted

December 17, 2020

Study Start

November 1, 2021

Primary Completion

September 30, 2024

Study Completion

November 30, 2024

Last Updated

January 10, 2025

Record last verified: 2025-01

Locations